Paweł Mielnik
Helse Førde(NO)Center for Rheumatology(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Systemic Lupus Erythematosus Research, COVID-19 Clinical Research Studies
Most-Cited Works
- → Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial(2017)793 cited
- → Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases(2021)152 cited
- → Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19(2021)121 cited
- → Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial(2019)118 cited
- → Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases(2021)118 cited
- → Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety(2010)72 cited
- → Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies(2006)59 cited
- → Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9(2021)37 cited
- → Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity(2010)32 cited
- → Celiac disease and risk of fracture in adults—a review(2014)28 cited